New drug creation project started to apply for benefits of several listed companies

2014-03-21 source: on March 19, China Securities Journal, the national health and Family Planning Commission issued a notice to start the application of 2015 major new drug creation In 2015, the project focuses on malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, mental diseases, diabetes, autoimmune diseases, drug-resistant pathogens infection, tuberculosis, major viral infectious diseases and other common and frequently occurring diseases (respiratory system and digestive system diseases) 10 To develop innovative drug research with important clinical value A number of listed companies are expected to receive funding and policy support It is reported that "major new drug creation" is a large-scale science and technology plan, and also a vane of domestic pharmaceutical research and development support It is planned to invest 40 billion yuan during the 12th Five Year Plan period, and another 75 billion yuan will be invested during the 13th Five Year Plan period to encourage new drug research and development Each round of support involves several domestic listed pharmaceutical enterprises In terms of subdivisions, the field of chemical medicine supports the targeting of neuropsychiatric diseases (bace, AMPA and other targets), metabolic diseases (PCSK9 and other targets), tumor targeting and immunotherapy, pulmonary hypertension and chronic obstructive pulmonary disease (SGC) Research on new mechanisms and new target drug varieties, focusing on supporting the research and development of innovative drugs with new mechanisms and no drugs on the market Traditional Chinese medicine focuses on supporting innovative clinical research of traditional Chinese medicine with outstanding clinical advantages (clinical trial approval has been obtained in recent 3 years, and clinical research has been carried out) In the field of Biopharmaceutics, we focus on supporting new structural antibodies, bispecific antibodies, antibody coupling drugs, new structural proteins and polypeptide drugs, biological analogues, and innovative varieties with new technologies and new processes for preparing new vaccines, combined vaccines and therapeutic vaccines, which have a good basis for drug resistance research In the field of core technology, new topics focus on the core generic technology of improving drug-forming properties, screening model based on cell drugs, drug-making evaluation technology for targeted drugs in cells, and transformation pharmaceutical technology based on the research of effective biomarkers In addition to the support of scientific research funds, the selected companies also enjoy the preferential treatment of new drug registration and approval, and have a special fast channel to ensure the approval efficiency of new drugs Several companies are expected to focus on benefits Hengrui pharmaceutical has several cancer target drugs under research and diabetes 1.1 new drugs; several 1.1 biological analogues under Tonghua Dongbao, a domestic insulin giant, are also in the research and development stage In general, according to the above key support directions, chemical pharmaceutical enterprises include Huabei pharmaceutical, Haizheng pharmaceutical, etc.; biological pharmaceutical enterprises include Watson bio, Baiyunshan, Haixin Co., Ltd., Zhongyuan Xiehe, Shanghai Laishi, etc.; traditional Chinese medicine direction includes Tongrentang, Tianshili, Yiling pharmaceutical, etc